Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) shares were down 7.7% during mid-day trading on Tuesday . The company traded as low as $14.87 and last traded at $14.89. Approximately 120,433 shares traded hands during mid-day trading, a decline of 85% from the average daily volume of 809,498 shares. The stock had previously closed at $16.13.
Analyst Ratings Changes
A number of equities analysts have recently issued reports on ZNTL shares. Wedbush increased their target price on Zentalis Pharmaceuticals from $12.00 to $15.00 and gave the stock a "neutral" rating in a report on Wednesday, February 28th. HC Wainwright reissued a "buy" rating and issued a $46.00 target price on shares of Zentalis Pharmaceuticals in a report on Wednesday, February 28th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $38.57.
Get Our Latest Stock Analysis on Zentalis Pharmaceuticals
Zentalis Pharmaceuticals Stock Performance
The stock has a market capitalization of $1.02 billion, a P/E ratio of -3.18 and a beta of 1.73. The stock has a 50-day simple moving average of $13.58 and a 200 day simple moving average of $14.67.
Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last announced its quarterly earnings data on Tuesday, February 27th. The company reported ($0.83) EPS for the quarter, beating analysts' consensus estimates of ($0.92) by $0.09. Equities analysts predict that Zentalis Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.
Insider Buying and Selling at Zentalis Pharmaceuticals
In other news, CFO Melissa B. Epperly sold 2,573 shares of the firm's stock in a transaction on Monday, February 12th. The stock was sold at an average price of $11.44, for a total value of $29,435.12. Following the transaction, the chief financial officer now directly owns 451,449 shares in the company, valued at approximately $5,164,576.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 6.10% of the company's stock.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in Zentalis Pharmaceuticals by 2.2% during the 4th quarter. Vanguard Group Inc. now owns 5,350,458 shares of the company's stock worth $81,059,000 after buying an additional 113,795 shares during the period. Eventide Asset Management LLC grew its holdings in shares of Zentalis Pharmaceuticals by 47.9% in the 4th quarter. Eventide Asset Management LLC now owns 11,559,975 shares of the company's stock valued at $175,134,000 after acquiring an additional 3,745,936 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Zentalis Pharmaceuticals by 6.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,904,065 shares of the company's stock valued at $43,998,000 after acquiring an additional 188,466 shares in the last quarter. Virtus ETF Advisers LLC grew its holdings in shares of Zentalis Pharmaceuticals by 54.3% in the 4th quarter. Virtus ETF Advisers LLC now owns 6,189 shares of the company's stock valued at $94,000 after acquiring an additional 2,177 shares in the last quarter. Finally, Barclays PLC grew its holdings in shares of Zentalis Pharmaceuticals by 98.1% in the 4th quarter. Barclays PLC now owns 219,518 shares of the company's stock valued at $3,326,000 after acquiring an additional 108,701 shares in the last quarter.
About Zentalis Pharmaceuticals
(
Get Free Report)
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.
See Also
Before you consider Zentalis Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zentalis Pharmaceuticals wasn't on the list.
While Zentalis Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
